Triumph Capital Management
ELDN icon

Triumph Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Triumph Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$801K Buy
316,509
+13,066
+4% +$43.9K 0.14% 158
2026
Q2 		$1.2M Buy
+303,443
New +$1.1M 0.22% 110

Other funds holding ELDN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Daytona Street Capital
Daytona Street Capital Saint Louis, Missouri $141M AUM 14.38% 1-Year Est. Return
Prodigy Asset Management
Prodigy Asset Management Omaha, Nebraska $335M AUM 5.94% 1-Year Est. Return
Farmers & Merchants Investments Inc
Farmers & Merchants Investments Inc Lincoln, Nebraska $4.16B AUM 24.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
PW Nova Financial Services
PW Nova Financial Services Newtown, Pennsylvania $491M AUM 22.36% 1-Year Est. Return

Triumph Capital Management's ELDN Position: Q3 2026 in Review

Triumph Capital Management increased its Eledon Pharmaceuticals (ELDN) stake by 4.3% in Q3 2026, buying an estimated $43.9K and bringing the position to 316,509 shares worth $801K. The position accounts for 0.14% of the portfolio, ranked #158.

Triumph Capital Management first reported a position in ELDN in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.2M in Q2 2026. 61 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

  • Triumph Capital Management held 316,509 shares of Eledon Pharmaceuticals worth $801K as of Q3 2026.
  • Triumph Capital Management bought 13,066 Eledon Pharmaceuticals shares in Q3 2026, an estimated $43.9K.
  • Eledon Pharmaceuticals made up 0.14% of Triumph Capital Management's portfolio in Q3 2026, its #158 holding.
  • Triumph Capital Management first reported a position in Eledon Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Triumph Capital Management's Eledon Pharmaceuticals position peaked at $1.2M in Q2 2026.
  • 61 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.